Y
Yu Shyr
Researcher at Vanderbilt University Medical Center
Publications - 582
Citations - 45668
Yu Shyr is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 98, co-authored 542 publications receiving 39527 citations. Previous affiliations of Yu Shyr include Vanderbilt University & Ninewells Hospital.
Papers
More filters
Journal ArticleDOI
LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.
Boris Sepesi,David R. Jones,Bryan F. Meyers,Jamie E. Chaft,Lynette M. Sholl,Yu Shyr,Karen Kelly,Jules Lin,Paul A. Bunn,John D. Minna,Valerie W. Rusch,Ignacio I. Wistuba,David J. Kwiatkowski,David P. Carbone,Lynne D. Berry,Jay M. Lee,Khaled A. Tolba,Mark G. Kris +17 more
TL;DR: The study will assess the feasibility of CGP to detect actionable oncogenic drivers in patients with suspected early-stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.
Journal ArticleDOI
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Namrata S Chandhok,Wei Wei,Ranjit S. Bindra,Stephanie Halene,Yu Shyr,Jing Li,Michael E. Berens,Chris Karlovich,S. Percy Ivy,Thomas Prebet +9 more
TL;DR: The PRIME trial is a proof of concept, biomarker-driven, multi-institution, phase II open label clinical trial to assess the overall response of IDH1/2 mutant relapsed/refractory AML and MDS to PARP inhibitor monotherapy with olaparib.
Journal ArticleDOI
Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry
Ang Li,Nicole M. Kuderer,Jeremy L. Warner,Aakash Desai,Dimpy P. Shah,Julie Fu,Monica Li,Rebecca L. Zon,Surbhi Shah,Shuchi Gulati,Ali Raza Khaki,Amit Kulkarni,Amro Elshoury,Michael A. Thompson,Petros Grivas,Gilberto Lopes,Yu Shyr,Nathan A. Pennell,Andrew Schmidt,Christopher R. Friese,Daniel G. Stover,Jaymin M. Patel,Balazs Halmos,Toni K. Choueiri,Solange Peters,Donna R. Rivera,Corrie A. Painter,Brian I. Rini,Gary H. Lyman,Jean M. Connors,Rachel P. Rosovsky +30 more
TL;DR: Multivariable adjustment is ongoing to identify independent risk factor for VTE and clarify the impact of pre-admission anticoagulant/antiplatelet use controlled for other potential confounders.
Journal ArticleDOI
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Joseph Kim,Dana Backlund Cardin,Ulka N. Vaishampayan,Shumei Kato,Steven R. Grossman,Peter M. Glazer,Yu Shyr,S. Percy Ivy,Patricia LoRusso +8 more
TL;DR: Cediranib and olaparib combination did not result in clinically meaningful activity in patients with metastatic pancreatic ductal adenocarcinoma without known BRCA mutation.
Journal ArticleDOI
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis.
Samuel M. Rubinstein,Divaya Bhutani,Ryan C. Lynch,Chih-Yuan Hsu,Yu Shyr,Shailesh Advani,Ruben A. Mesa,Sanjay Mishra,Daniel Mundt,Dimpy P. Shah,R. Alejandro Sica,Keith Stockerl-Goldstein,Catherine Stratton,Matthias Weiss,Alicia Beeghly-Fadiel,Melissa K. Accordino,Sarit Assouline,Joy Awosika,Ziad Bakouny,Babar Bashir,Stephanie Berg,Mehmet Asim Bilen,Cecilia A. Castellano,Jacob C Cogan,Devendra Kc,Christopher R. Friese,Shilpa Gupta,Daniel Hausrath,Clara Hwang,Nathalie A. Johnson,Monika Joshi,Anup Kasi,Elizabeth Klein,Vadim S. Koshkin,Nicole M. Kuderer,Daniel Kwon,Chris Labaki,Tahir Latif,Eric Lau,Xuanyi Li,Gary H. Lyman,Rana R. McKay,Gayathri Nagaraj,Amanda Nizam,Taylor K. Nonato,Adam J. Olszewski,Hyma Polimera,Andrew J. Portuguese,Matthew Puc,Pedram Razavi,Rachel Rosovski,Andrew Schmidt,Sumit A. Shah,Aditi Shastri,Christopher Su,Pallawi Torka,Trisha Wise-Draper,Leyre Zubiri,Jeremy L. Warner,M. A. Thomson +59 more
TL;DR: It is shown that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared to control populations of patients with non-B-LYmphoid hematologicmalignancies and that those who received anti-cancer therapy within 12 months of CO VID-19 diagnosis experienced increased COVID19 severity.